UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: March 31, 2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

Commission File Number: 001-39553

AMESITE INC.

(Exact name of registrant as specified in its charter)

Delaware		82-3431718
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

607 Shelby Street Suite 700 PMB 214 Detroit, MI		48226
(Address of principal executive offices)		(Zip Code)

(734) 876-8140

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001		AMST		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

There were 4,572,713 shares of the registrant’s common stock issued and outstanding as of May 15, 2025.

TABLE OF CONTENTS

		Page

PART I - FINANCIAL INFORMATION		1

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)		1
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS		15
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK		21
ITEM 4. CONTROLS AND PROCEDURES		21

PART II - OTHER INFORMATION		22

ITEM 1. LEGAL PROCEEDINGS		22
ITEM 1A. RISK FACTORS		22
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS		23
ITEM 3. DEFAULTS UPON SENIOR SECURITIES		23
ITEM 4. MINE SAFETY DISCLOSURES		23
ITEM 5. OTHER INFORMATION		23
ITEM 6. EXHIBITS		24

SIGNATURES		25

-i-

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains “forward-looking statements” which include information relating to future events, future financial performance, financial projections, strategies, expectations, competitive environment and regulation. Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information we have when those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to a number of risks, and uncertainties and assumptions that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. These risks are more fully described in the “Risk Factors” section of this Quarterly Report on Form 10-Q. The following is a summary of such risks:

	●	our healthcare app’s ability to enable our clients to offer AI-driven tools and resources to do their jobs more efficiently and effectively, without becoming software tech companies;

	●	our healthcare app’s ability to result in opportunistic incremental revenue for our clients through use of AI-driven tools;

	●	our ability to continue as a going concern;

	●	our ability to obtain additional funds for our operations;

	●	our ability to obtain and maintain intellectual property protection for our technologies and our ability to operate our business without infringing the intellectual property rights of others;

	●	our reliance on third parties to conduct our business and studies;

	●	our reliance on third party designers, suppliers, and partners to provide and maintain our platform;

	●	our ability to attract and retain qualified key management and technical personnel;

	●	our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act, or JOBS Act;

	●	our financial performance;

	●	the impact of government regulation and developments relating to our competitors or our industry; and

	●	other risks and uncertainties, including those listed under the caption “Risk Factors.”

These statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled “Item 1A. Risk Factors” and elsewhere in our Annual Report on Form 10-K/A for the year ended June 30, 2024, filed with the Securities and Exchange Commission (“SEC”) on January 2, 2025.

Any forward-looking statements in this Quarterly Report on Form 10-Q reflect our current view with respect to future events and are subject to these and other risks, uncertainties and assumptions relating to our business, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Quarterly Report on Form 10-Q, and the documents that we reference herein and have filed as exhibits hereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

This Quarterly Report on Form 10-Q also contains, or may contain, estimates, projections and other information concerning our industry, our business and the markets for our products, including data regarding the estimated size of those markets and their projected growth rates. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which these data are derived.

-ii-

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

Contents

Condensed Financial Statements		Page
Condensed Balance Sheets (unaudited)		2

Condensed Statements of Operations (unaudited)		3

Condensed Statements of Stockholders’ Equity (unaudited)		4

Condensed Statements of Cash Flows (unaudited)		5

Notes to Condensed Financial Statements		6

-1-

Amesite, Inc.

Condensed Balance Sheets (unaudited)

	March 31, 2025			June 30, 2024
Assets
Current Assets
Cash and cash equivalents	$	2,858,963		$	2,071,016
Restricted cash		100,000			100,000
Accounts receivable		4,440			30,060
Prepaid expenses and other current assets		175,721			403,489
Total current assets		3,139,124			2,604,565

Noncurrent Assets
Property and equipment - net		45,773			64,784
Capitalized software - net		624,319			644,828
Total noncurrent assets		670,092			709,612

Total assets	$	3,809,216		$	3,314,177

Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable	$	30,937		$	48,907
Accrued compensation		167,184			655,275
Deferred revenue		3,835			-
Other accrued liabilities		8,998			94,283
Total current liabilities		210,954			798,465

Stockholders’ Equity
Common stock, $.0001 par value; 100,000,000 shares authorized; 4,572,713 and 2,592,440 shares issued and outstanding at March 31, 2025 and June 30, 2024, respectively		458			255
Preferred stock, $.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding at March 31, 2025 and June 30, 2024		-			-
Additional paid-in capital		44,124,405			40,348,958
Accumulated deficit		(40,526,601	)		(37,833,501	)
Total stockholders’ equity		3,598,262			2,515,712

Total liabilities and stockholders’ equity	$	3,809,216		$	3,314,177

See accompanying Notes to Condensed Financial Statements.

-2-

Amesite, Inc.

Condensed Statements of Operations (unaudited)

	Three Months Ended March 31,						Nine Months Ended March 31,
	2025			2024			2025			2024
Net Revenue	$	30,690		$	34,261		$	54,700		$	139,037

Operating Expenses
General and administrative expenses		428,465			1,134,867			1,866,239			2,016,930
Technology and content development		172,098			223,845			523,623			888,503
Sales and marketing		117,849			139,333			410,773			603,462
Total operating expenses		718,412			1,498,045			2,800,635			3,508,895

Loss from Operations		(687,722	)		(1,463,784	)		(2,745,935	)		(3,369,858	)

Other Income
Interest income		24,304			37,872			52,835			147,642
Total other income		24,304			37,872			52,835			147,642

Net Loss	$	(663,418	)	$	(1,425,912	)	$	(2,693,100	)	$	(3,222,216	)

Earnings (loss) per Share
Basic and diluted loss per share	$	(0.16	)	$	(0.56	)	$	(0.85	)	$	(1.27	)
Weighted average shares outstanding		4,054,939			2,542,440			3,177,932			2,542,440

See accompanying Notes to Condensed Financial Statements.

-3-

Amesite, Inc.

Condensed Statements of Stockholders’ Equity (unaudited)

					Additional
	Common Stock				Paid-In			Accumulated
	Shares		Amount		Capital			Deficit			Total
Balance - July 1, 2024		2,542,440	$	255	$	40,348,958		$	(37,833,501	)	$	2,515,712
Net loss		-		-		-			(908,045	)		(908,045	)
Issuance of common stock for consulting services		250,000		25		654,975			-			655,000
Stock-based compensation		-		-		65,440			-			65,440
Balance - September 30, 2024		2,792,440		280		41,069,373			(38,741,546	)		2,328,107
Net loss		-		-		-			(1,121,637	)		(1,121,637	)
Stock-based compensation		-		-		40,995			-			40,995
Balance - December 31, 2024		2,792,440		280		41,110,368			(39,863,183	)		1,247,465
Net loss		-		-		-			(663,418	)		(663,418	)
Public offering common stock purchases, net of offering costs of $1,164,050		1,201,667		120		2,440,711			-			2,440,831
Warrants issued		-		-		95,984			-			95,984
Stock-based compensation, net of forfeitures		-		-		(144,609	)		-			(144,609	)
Restricted shares in exchange for accrued director compensation		578,606		58		621,951			-			622,009
Balance - March 31, 2025	$	4,572,713	$	458	$	44,124,405		$	(40,526,601	)	$	3,598,262

					Additional
	Common Stock				Paid-In			Accumulated
	Shares		Amount		Capital			Deficit			Total
Balance - July 1, 2023		2,542,440	$	255	$	39,514,489		$	(33,430,319	)	$	6,084,425
Net loss		-		-		-			(890,693	)		(890,693	)
Stock-based compensation		-		-		55,098			-			55,098
Balance - September 30, 2023		2,542,440		255		39,569,587			(34,321,012	)		5,248,830
Net loss		-		-		-			(905,611	)		(905,611	)
Stock-based compensation		-		-		33,133			-			33,133
Balance - December 31, 2023		2,542,440		255		39,602,720			(35,226,623	)		4,376,352
Net loss		-		-		-			(1,425,912	)		(1,425,912	)
Stock-based compensation		-		-		672,507			-			672,507
Balance - March 31, 2024		2,542,440	$	255	$	40,275,227		$	(36,652,535	)	$	3,622,947

See accompanying Notes to Condensed Financial Statements.

-4-

Amesite, Inc.

Condensed Statements of Cash Flows (unaudited)

	Nine Months Ended
	March 31,
	2025			2024
Cash Flows from Operating Activities
Net Loss	$	(2,693,100	)	$	(3,222,216	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		331,719			414,177
Stock-based compensation expense		(38,174	)		760,738
Warrants issued for underwriting fee		95,984			-
Changes in operating assets and liabilities which used cash:
Accounts receivable		25,620			15,000
Prepaid expenses and other current assets		227,768			(73,476	)
Accounts payable		(17,970	)		(7,063	)
Accrued compensation		133,799			(900	)
Deferred revenue		3,835			(52,083	)
Other accrued liabilities		(85,285	)		6,459
Net cash and cash equivalents used in operating activities		(2,015,804	)		(2,159,364	)

Cash Flows from Investing Activities
Purchase of property and equipment		-			(1,166	)
Investment in capitalized software		(292,199	)		(227,600	)
Net cash and cash equivalents used in investing activities		(292,199	)		(228,766	)

Cash Flows from Financing Activities
Proceeds from the sale of common stock		3,095,950			-
Net cash and cash equivalents provided by financing activities		3,095,950			-

Net increase (decrease) in cash, cash equivalents, and restricted cash		787,947			(2,388,130	)
Cash, cash equivalents, and restricted cash - Beginning of period		2,171,016			5,360,661
Cash, cash equivalents, and restricted cash - End of period	$	2,958,963		$	2,972,531

SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES:
Settle restricted stock units through common stock issuance to directors	$	600,000		$	-
Issuance of common stock for accrued director compensation	$	21,890		$	-
Issuance of common stock for public offering consulting expenses	$	655,000		$	-

See accompanying Notes to Condensed Financial Statements.

-5-

Amesite, Inc.

Notes to Condensed Financial Statements

Note 1 - Nature of Business

Amesite Inc. (the “Company”) was incorporated in November 2017. Amesite is a pioneering technology company specializing in the development and marketing of B2C and B2B AI-driven solutions, including its higher ed platform and healthcare app. Leveraging its proprietary AI infrastructure, Amesite offers cutting-edge applications that cater to both individual and professional needs. NurseMagic™, the company’s mobile healthcare app, streamlines creation of nursing notes and documentation tasks, enhances patient communication, and offers personalized guidance to nurses on patient care, medications, and handling challenging workplace situations.

Note 2 - Significant Accounting Policies

Basis of Presentation

The condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and considering the requirements of the United States Securities and Exchange Commission (“SEC”). The Company has a June 30 fiscal year.

In the opinion of management, the condensed financial statements of the Company as of March 31, 2025 and for the three and nine months ended March 31, 2025 and 2024 include all adjustments and accruals, consisting only of normal, recurring accrual adjustments, which are necessary for a fair presentation of the results for the interim periods. These interim results are not necessarily indicative of results for a full year.

Certain information and footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed in or omitted from this report pursuant to the rules and regulations of the SEC. These condensed financial statements should be read together with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K/A for the year ended June 30, 2024.

Going Concern

The accompanying condensed financial statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

The Company is developing its customer base and has not completed its efforts to establish a stabilized source of revenue sufficient to cover its expenses. The Company has had a history of net losses and negative cash flows from operating activities since inception and expects to continue to incur net losses and use cash in its operations in the foreseeable future.

The Company has considered both quantitative and qualitative factors that are known or reasonably known as of the date of these condensed financial statements are issued and concluded that there are conditions present in the aggregate that raise substantial doubt about the Company’s ability to continue as a going concern. In response to the conditions, management plans include generating cash by completing financing transactions, which may include offerings of common stock. However, these plans are subject to market conditions, and are not within the Company’s control, and therefore, cannot be deemed probable. There is no assurance that the Company will be successful in implementing their plans. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern. The condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

-6-

Use of Estimates

The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all investments with an original maturity of three months or less when purchased to be cash equivalents. The total amount of bank deposits (checking and savings accounts) insured by the FDIC at year end was $250,000.

As of June 30, 2024, the Company reclassified a portion of its cash balance to “Restricted Cash” in the balance sheets to reflect amounts pledged as collateral for the Company’s credit card facility. As of March 31, 2025 and June 30, 2024, restricted cash totaled $100,000.

The following is a reconciliation of cash, cash equivalents, and restricted cash reported on the balance sheet and those reported on the statement of cash flows at March 31, 2025 and 2024.

	March 31,		March 31,
	2025		2024

Cash and cash equivalents	$	2,858,963	$	2,972,531
Restricted cash		100,000		-
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$	2,958,963	$	2,972,531

Prepaid Expenses

The Company considers all items incurred for future services to be prepaid expenses. At March 31, 2025 and June 30, 2024, the Company’s prepaid expenses consisted of the following.

	March 31,		June 30,
	2025		2024

Insurance	$	104,039	$	70,830
Stock-based compensation		-		300,000
Other general and administrative		71,682		32,659

	$	175,721	$	403,489

Property and Equipment

Property and equipment are recorded at cost. The straight-line method is used for computing depreciation and amortization. Assets are depreciated over their estimated useful lives. The cost of leasehold improvements is depreciated (amortized) over the lesser of the length of the related leases or the estimated useful lives of the assets. Costs of maintenance and repairs are charged to expense when incurred.

		Depreciable Life - Years
Leasehold improvements		Shorter of estimated lease term or 10 years
Furniture and fixtures		7 years
Computer equipment and software		5 years

-7-

Capitalized Software Costs

The Company capitalizes costs incurred in the development of software for its customers, including the costs of the software, materials, consultants, and payroll and payroll related costs for employees incurred in developing computer software. Software development projects generally include three stages: the preliminary project stage (all costs are expensed as incurred), the application development stage (certain costs are capitalized and certain costs are expensed as incurred) and the post-implementation/operation stage (all costs are expensed as incurred). Capitalization of costs requires judgment in determining when a project has reached the application development stage, the proportion of time spent in the application development stage, and the period over which we expect to benefit from the use of that software. Once the software is placed in service, these costs are amortized on the straight-line method over the estimated useful life of the software, which is generally three years.

	March 31,		June 30,
	2025		2024
Beginning capitalized software	$	3,993,691	$	3,618,991
Additions		292,200		374,700
Ending capitalized software		4,285,891		3,993,691

Beginning accumulated amortization		3,348,863		2,840,545
Amortization expense		312,709		508,318
Ending accumulated amortization		3,661,572		3,348,863

Capitalized software - net	$	624,319	$	644,828

Amortization expense for the nine months ended March 31, 2025 and 2024 was $312,709 and $395,165, respectively and included as part of “Technology and content development” in the Statements of Operations. Amortization expense for the three months ended March 31, 2025 and 2024 was $94,172 and $113,153, respectively and included as part of “Technology and content development” in the Statements of Operations.

Revenue Recognition

We generate our revenue from contractual arrangements with our clients to provide a comprehensive platform of integrated technology and technology enabled services related to product offerings. During the nine months ended March 31, 2025 and 2024, we recognized revenue from contracts with customers of $54,700 and $139,037, respectively, related to services provided over time. During the three months ended March 31, 2025 and 2024, we recognized revenue from contracts with customers of $30,690 and $34,261, respectively, related to services provided over time.

Performance Obligations and Timing of Recognition

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.

This performance obligation is satisfied as the partners receive and consume benefits, which occur ratably over the contract term.

Occasionally, we provide professional services, such as custom development, non-complex implementation activities, training, and other various professional services. We evaluate these services to determine if they are distinct and separately identifiable in the context of the contract. In our contracts with customers that contain multiple performance obligations as a result of this assessment, we allocate the transaction price to each separate performance obligation on a relative standalone selling price basis. Standalone selling prices of our solutions and services are typically estimated based on observable transactions when the solutions or services are sold on a standalone basis. When standalone selling prices are not observable, we utilize a cost-plus margin approach to allocate the transaction price.

We also receive fees that are fixed in nature, such as annual license and maintenance charges, in place of or in conjunction with variable consideration. The fees are recognized ratably over the service period of the contract that the Company’s platform is made available to the customer (i.e., the customer simultaneously receives and consumes the benefit of the software over the contract service period).

For the three and nine months ended March 31, 2025 and 2024, all revenue recognized has been recognized over the related contract periods. For the three and nine months ended March 31, 2025, one customer represents 37% and 62%, respectively, of total revenue. For the three and nine months ended March 31, 2024, three customers represented 99% and 24% each of total revenue.

-8-

Accounts Receivable and Deferred Liabilities

Balance sheet items related to contracts consist of accounts receivable (net), contract assets, and deferred liabilities on our condensed balance sheets. Accounts receivable is stated at net realizable value, and we utilize the allowance method to provide for doubtful accounts based on management’s evaluation of the collectability of the amounts due. Our estimates are reviewed and revised periodically based on historical collection experience and a review of the current status of accounts receivable. Historically, actual write-offs for uncollectible accounts have not significantly differed from prior estimates. There was no allowance for doubtful accounts on accounts receivable balances as of March 31, 2025 or June 30, 2024.

Deferred liabilities as of each balance sheet date represent the excess of amounts billed or received as compared to amounts recognized in revenue on our condensed statements of operations as of the end of the reporting period, and such amounts are reflected as a current liability on our condensed balance sheets as deferred revenue. We generally receive payments prior to completion of the service period and our performance obligations. These payments are recorded as deferred liability until the services are delivered or until our obligations are otherwise met, at which time revenue is recognized.

Some contracts also involve annual license fees, for which upfront amounts are received from customers. In these contracts, the license fees received in advance of the platform’s launch are recorded as deferred liabilities.

The following table provides information on the changes in the balance of deferred liabilities:

	Nine Months Ended			Fiscal Year Ended
	March 31,			June 30,
	2025			2024
Opening balance	$	-		$	53,958
Plus billings		38,985			112,923
Less revenue recognized		(35,150	)		(166,881	)
	$	3,835		$	-

Revenue recognized during the nine months ended March 31, 2025 and year ended June 30, 2024 that was included in the deferred revenue balance that existed in the opening balance of each year was approximately $-0- and $54,000, respectively.

The deferred liability balance as of March 31, 2025 is expected to be recognized over the next 12 months.

Stock-Based Compensation

We have issued four types of stock-based awards under our stock plans: stock options, restricted stock units, deferred stock units, and stock warrants. All stock-based awards granted to employees, directors and independent contractors are measured at fair value at each grant date. We rely on the Black-Scholes option pricing model for estimating the fair value of stock-based awards granted, and expected volatility is based on the historical volatility of the Company’s stock prices. Stock options generally vest over two years from the grant date and generally have ten-year contractual terms. Restricted stock units generally have a term of 12 months from the closing date of the agreement. Deferred stock units originate from directors deferring their quarterly cash compensation and vest (and are issuable) upon their departure. Stock warrants issued have a term of five years. Information about the assumptions used in the calculation of stock-based compensation expense is set forth in Note 3 in the Notes to Condensed Financial Statements.

-9-

Technology and Content Development

Technology and content development expenditures consist primarily of personnel and personnel-related expense and contracted services associated with the maintenance of our platform as well as hosting and licensing costs and are charged to expense as incurred. It also includes amortization of capitalized software costs and research and development costs related to improving our platform and creating content that are charged to expense as incurred.

Fair Value Measurements

Accounting standards require certain assets and liabilities be reported at fair value in the condensed financial statements and provide a framework for establishing that fair value. The framework for determining fair value is based on a hierarchy that prioritizes the inputs and valuation techniques used to measure fair value.

Fair values determined by Level 1 inputs use quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.

Fair values determined by Level 2 inputs use other inputs that are observable, either directly or indirectly. These Level 2 inputs include quoted prices for similar assets and liabilities in active markets and other inputs such as interest rates and yield curves that are observable at commonly quoted intervals.

Level 3 inputs are unobservable inputs, including inputs that are available in situations where there is little, if any, market activity for the related asset. These Level 3 fair value measurements are based primarily on management’s own estimates using pricing models, discounted cash flow methodologies, or similar techniques.

In instances wherein inputs used to measure fair value fall into different levels in the above fair value hierarchy, fair value measurements in their entirety are categorized based on the lowest level input that is significant to the valuation. The Company’s assessment of the significance of particular inputs to these fair value measurements requires judgment and considers factors specific to each asset or liability.

Income Taxes

A current tax liability or asset is recognized for the estimated taxes payable or refundable on tax returns for the year. Deferred tax liabilities or assets are recognized for the estimated future tax effects of temporary differences between financial reporting and tax accounting.

Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the enactment date.

Net Earnings (Loss) per Share

At March 31, 2025 and June 30, 2024, the Company had 603,971 and 633,000, respectively, potentially dilutive shares of common stock related to common stock options and warrants as determined using the if-converted method. For the three months and nine months ended March 31, 2025 and 2024, the dilutive effect of common stock options and common stock warrants has not been included in the average shares outstanding for the calculation of net loss per share as the effect would be anti-dilutive as a result of our net losses in these periods.

-10-

Subsequent Events

The Company evaluated subsequent events through the date this Form 10-Q was filed and has determined that no events have occurred that would require recognition or disclosure in the condensed financial statements.

Risks and Uncertainties

The Company operates in an industry subject to rapid change. The Company’s operations will be subject to significant risk and uncertainties including financial, operational, technological, and other risks associated with an early-stage company, including the potential risk of business failure.

Recently issued accounting standards

In November 2023, the Financial Accounting Standard Board (the “FASB”) issued Accounting Standard Updates (“ASU”) No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”),” which requires a public entity to disclose significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”), a description of other segment items by reportable segment, and an explanation of any additional measures the CODM uses in deciding how to allocate resources, and extend nearly all annual segment reporting requirements to quarterly reporting requirements. In addition, entities with a single reportable segment must now provide all segment disclosures required in ASC 280, including the new disclosures for reportable segments under the amendments in ASU 2023-07. The new guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, and early adoption is permitted. The guidance will be applied on a retrospective basis, with such disclosures to be made in regard to all prior periods presented in the financial statements.

In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09),” which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual periods beginning after December 31, 2024. Early adoption is permitted. Upon adoption, the guidance can be applied prospectively or retrospectively. The Company is currently evaluating the guidance to determine its impact on our condensed financial statements and related disclosures.

In November 2024, the FASB issued ASU No. 2024-03 “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40)” which requires disclosure each reporting period, in the notes to the financial statements, of specified information about certain costs and expenses. For public business entities, the new requirements will be effective for annual periods beginning after December 15, 2026. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the effect of adopting this ASU.

Note 3 - Stock-Based Compensation

The Company’s Equity Incentive Plan (the “Plan”) permits the grant of stock options, stock appreciation rights, restricted stock, restricted stock units, and deferred stock units to officers, employees, directors, consultants, agents, and independent contractors of the Company. The Company believes that such awards align the interests of its employees, directors, and consultants with those of its stockholders.

Option awards are generally granted with an exercise price equal to the market price of the Company’s stock at the date of grant; those option awards generally vest over two years from the grant date and generally have ten-year contractual terms. Certain option awards provide for accelerated vesting (as defined in the Plan).

The Company estimates the fair value of each option award using a Black Scholes Model (“BSM”). Expected volatilities are based on historical volatility of the Company’s stock. The Company uses historical data to estimate option exercise within the valuation model or estimates the expected option exercise when historical data is unavailable. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The Company has not paid any dividends on common stock since its inception and does not anticipate paying dividends on its common stock in the foreseeable future. When calculating the amount of annual compensation expense, the Company has elected not to estimate forfeitures and instead accounts for forfeitures as they occur.

1,200 and 0 options were granted for the nine months ended March 31, 2025 or 2024, respectively. As of March 31, 2025, there were approximately $27,000 of total unrecognized compensation costs for employees and non-employees related to nonvested options. These costs are expected to be recognized through September 2027.

-11-

A summary of options terminated, as well as those that vested, during the nine months ended March 31, 2025 is presented below:

Options	Number of Shares			Weighted Average Exercise Price			Weighted Average Remaining Contractual Term (in years)
Outstanding at July 1, 2024		235,219		$	22.05			5.6
Terminated		(69,421	)		(19.64	)		(2.31	)
Additional vesting		9,112			10.10			4.8
Outstanding and vested at March 31, 2025		174,910		$	21.19			5.1

A summary of options terminated, as well as those that vested, during the three months ended March 31, 2025 is presented below:

Options	Number of Shares			Weighted Average Exercise Price			Weighted Average Remaining Contractual Term (in years)
Outstanding at January 1, 2025		241,128		$	20.76			5.1
Terminated		(69,421	)		(19.64	)		(2.31	)
Additional vesting		3,203			18.53			7.14
Outstanding and vested at March 31, 2025		174,910		$	21.19			5.1

On September 29, 2021, the board of directors approved changes to our director compensation program for fiscal year 2022 and beyond. The board instituted an annual cash retainer for directors in the amount of $48,000 per director with an additional retainer for the chair of our Compensation Committee and Audit Committee of $7,500 and $10,000, respectively. Directors can choose to receive deferred stock units in lieu of cash payments. For the nine months ended March 31, 2025, $153,375 in deferred stock units were awarded and $41,625 in cash compensation was paid. For the three months ended March 31, 2025, $52,375 in deferred stock units were awarded.

On December 23, 2024, two directors resigned before their deferred stock units vested on December 31, 2024. Accordingly, a liability was recorded at December 31, 2024 to compensate them for their service for the partial quarter. During the three months ended March 31, 2025, 2,185 shares of common stock were issued to each director valued at the closing price of the stock on their resignation date, totaling $10,945 each, or $21,890 in total. This is included in stock-based compensation in the accompanying financial statements.

A summary of deferred stock units terminated/settled, as well as those that vested, during the three and nine months ended March 31, 2025 is presented below:

				Weighted Average
	Number of			Exercise
	Shares			Price
Nine months ended:
Outstanding, June 30, 2024		207,342		$	3.64
Issued		55,258			2.78
Terminated/Settled		(92,063	)		2.89
Outstanding, March 31, 2025		170,537		$	2.89

Three months ended:
Outstanding, December 31, 2024		240,957		$	2.91
Issued		21,643			2.42
Terminated/Settled		(92,063	)		2.89
Outstanding, March 31, 2025		170,537		$	2.89

Note: the weighed average remaining contractual term is not applicable since these do not vest until the director leaves service.

-12-

Note: the weighed average remaining contractual term is not applicable since these do not vest until the director leaves service.

On September 29, 2021, the board of directors approved changes to our director compensation program for fiscal year 2022 and beyond. The board instituted annual restricted stock units (RSU) for directors in the amount of $100,000 per director. These restricted stock units vest on their one year anniversary if the director served the entire year. During the three months ended March 31, 2025, the Company issued the vested RSUs.

A summary of restricted stock units terminated, as well as those that vested, during the three and nine months ended March 31, 2025 is presented below:

				Weighted Average		Weighted
	Number of			Exercise		Average
	Shares			Price		Term
Nine months ended:
Outstanding, June 30, 2024		555,432		$	3.24		-
Issued		165,288			2.42		0.93
Terminated/Resigned		(73,260	)		2.73		-
Settled		(482,172	)		3.24		-
Outstanding, March 31, 2025		165,288		$	2.42		0.93

Three months ended:
Outstanding, December 31, 2024		555,432		$	3.24		-
Issued		165,288			2.42		0.93
Terminated/Resigned		(73,260	)		2.73		-
Settled		(482,172	)		3.24		-
Outstanding, March 31, 2025		165,288		$	2.42		0.93

On May 3, 2024, the board of directors of the Company approved an amendment to the Company’s 2018 Equity Incentive Plan (the “2018 Plan”) to increase the number of shares available for issuance under the 2018 Plan by 508,488 shares and increase the number of shares that may be issued pursuant to the exercise of incentive stock options by 508,488 shares. The amendment to the 2018 Plan is intended to ensure that the Company can continue to provide an incentive to employees, directors and consultants by enabling them to share in the Company’s future growth. The amendment to the 2018 Plan was approved by the Company’s stockholders at the Company’s special meeting on June 18, 2024.

On July 11, 2024, the Company issued 250,000 shares of common stock to a consultant under an agreement for activities related to potential future financing. The $655,000 market value of those shares is reflected in the Company’s common stock and additional paid in capital accounts was capitalized as deferred issuance costs in current assets until the financing was completed January 8, 2025. At which time, these costs were recognized as an expense against the proceeds of the public offering pursuant to ASC 340-10-S99-1 (see Note 4).

On March 7, 2025, the Board of Directors authorized the issuance of 247,932 common stock shares for the 2023 common stock grant to the non-employee directors totaling $100,000 per director. Accordingly the $600,000 in accrued compensation on the balance sheet at June 30, 2024 was recognized in equity during the quarter ended March 31, 2025. Additionally, the Board of Directors authorized the settlement of deferred stock units to two resigned directors, totaling 96,434 shares of common stock issued.

-13-

During the quarter ended March 31, 2025, the shares due to directors from the 2022 restricted stock unit grant were issued, totaling 87,720 shares of common stock. Additionally, the director restricted stock unit grants for 2024 issued and vested, totaling 146,520 shares of common stock.

Lastly, the Board of Directors approved the issuance of 200,000 shares plus an additional 100,000 shares pursuant to the Company's 2018 Equity Incentive Plan to be issuable at the sole discretion of the Chief Executive Officer.

As of March 31, 2025, the Company has 528,456 shares of common stock available for granting under the Plan.

Note 4 - Warrants

On January 7, 2025, the Company entered into an underwriting agreement with Laidlaw & Company (UK) Ltd. (“Laidlaw”), as representatives of several underwriters to issue and sell 1,201,667 shares of the Company’s common stock at a purchase price of $3.00 per share. As part of the offering, the Company agreed to issue the underwriters, or their designees, warrants to purchase a number of shares of common stock equal to five percent (5%) of the number of shares sold to the public at an at an exercise price equal to 125.0% of the offering price per share of common stock, or $3.75 per share. The fair value of the warrants issued was approximately $96,000 based on the following inputs and assumptions using the BSM: (i) expected stock price volatility of 108%; (ii) risk free rate of 3.65%; and (iii) expected life of the warrants of 5 years. No warrants were issued during the nine months ended March 31, 2024.

A summary of warrant activity during the nine months ended March 31, 2025 is presented below:

Warrants	Number of Shares			Weighted Average Exercise Price			Weighted Average Remaining Contractual Term (in years)
Outstanding at July 1, 2024		397,781		$	8.25			3.5
Expired		(13,783	)		(19.64	)		(0	)
Additional issuances		45,063			10.10			4.8
Outstanding and vested at March 31, 2025		429,061		$	11.03			3.0

Note 5 - Income Taxes

For the nine months ended March 31, 2025 and prior periods since inception, the Company’s activities have not generated taxable income or tax liabilities.

The Company has approximately $29.9 million of net operating loss carryforwards available to reduce future income taxes, of which approximately $17,000 of net operating loss carryforwards expire in 2037. Due to uncertainty as to the realization of the net operating loss carryforwards and other deferred tax assets as a result of the Company’s limited operating history and operating losses since inception, a full valuation allowance has been recorded against the Company’s deferred tax assets. Accordingly, the Company has not recognized an income tax benefit on the Condensed Statements of Operations for the three or nine months ended March 31, 2025 and 2024.

-14-

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read together with our unaudited condensed financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our audited financial statements and related notes for the year ended June 30, 2024 included in our Annual Report on Form 10-K/A filed with the SEC on January 2, 2025. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties, and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors. We discuss factors that we believe could cause or contribute to these differences below and elsewhere in this Quarterly Report on Form 10-Q, including those factors set forth in the section entitled “Cautionary Statement Regarding Forward-Looking Statements” and in the section entitled “Risk Factors” in Part II, Item 1A.

Overview

The following discussion highlights our results of operations and the principal factors that have affected our financial condition as well as our liquidity and capital resources for the nine months ended March 31, 2025 and provides information that management believes is relevant for an assessment and understanding of the statements of financial condition and results of operations presented herein. The following discussion and analysis are based on our unaudited condensed financial statements contained in this Quarterly Report on Form 10-Q, which we have prepared in accordance with United States generally accepted accounting principles, or GAAP, and the requirements of the SEC. You should read the discussion and analysis together with such financial statements and the related notes thereto.

We are not currently profitable, and we cannot provide any assurance that we will ever be profitable. We incurred a net loss of $2,693,100 for the nine months ended March 31, 2025, and we incurred a net loss of $40.5 million for the period from November 14, 2017 (date of incorporation) to March 31, 2025.

The assessment of the Company’s ability to meet its future obligations is inherently judgmental, subjective and susceptible to change. Based on their current forecast, management believes that it will have sufficient cash and cash equivalents to maintain the Company’s planned operations for the next twelve months following the issuance of these condensed financial statements; however, there is uncertainty in the forecast and therefore the Company cannot assert that it is probable. The Company has considered both quantitative and qualitative factors that are known or reasonably knowable as of the date of these condensed financial statements are issued and concluded that there are conditions present in the aggregate that raise substantial doubt about the Company’s ability to continue as a going concern.

In response to the conditions, management plans include generating cash by completing financing transactions, which may include offerings of common stock. However, these plans are subject to market conditions, and are not within the Company’s control, and therefore, cannot be deemed probable. There is no assurance that the Company will be successful in implementing their plans. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern.

-15-

Basis of Presentation

The financial statements contained herein have been prepared in accordance with GAAP and the requirements of the SEC.

Financial Position, Liquidity, and Capital Resources

During the period from November 14, 2017 (date of incorporation) to September 30, 2020, we raised net proceeds of approximately $11,760,000 from private placement financing transactions (stock and debt). On September 25, 2020, we completed the Offering of 250,000 shares of our common stock, $0.0001 par value per share, at an offering price of $60.00 per share (total net proceeds of approximately $12.8 million after underwriting discounts, commissions, and other offering costs).

On August 2, 2021, we entered into a purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), under which, subject to specified terms and conditions, we may sell up to $16.5 million shares of common stock. Our net proceeds under the Purchase Agreement will depend on the frequency of sales and the number of shares sold to Lincoln Park and the prices at which we sell shares to Lincoln Park. On August 2, 2021, we sold 63,260 shares of our common stock to Lincoln Park in an initial purchase under the Purchase Agreement for a total purchase price of $1,500,000. We also issued 12,727 shares of our common stock to Lincoln Park as consideration for its irrevocable commitment to purchase our common stock under the Purchase Agreement. Total common stock reserved for this Purchase Agreement is 274,014 shares.

On February 16, 2022, we closed on a public offering of common stock and received approximately $2.51 million of cash proceeds, net of underwriting discounts, commissions, and other offering costs.

On September 1, 2022, we closed on a public offering of common stock and concurrent private placement of warrants and received approximately $1.85 million of cash proceeds, net of underwriting discounts, commissions, and other offering costs.

On January 8, 2025, we closed on a public offering of our common stock and received approximately $3.1 million of cash proceeds, net of underwriting discounts, commissions and other offering costs.

As of March 31, 2025, our cash and cash equivalent balance totaled $2,858,963.

Going Concern

-16-

Critical Accounting Policies and Significant Judgments and Estimates

This management’s discussion and analysis of financial condition and results of operations is based on our condensed financial statements, which have been prepared in accordance with GAAP. The preparation of these condensed financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the condensed financial statements, and the reported amounts of revenue and expenses during the reported period. In accordance with GAAP, we base our estimates on historical experience and on various other assumptions we believe to be reasonable under the circumstances. Actual results may differ from these estimates if conditions differ from our assumptions. While our significant accounting policies are more fully described in Note 2 in the “Notes to Condensed Financial Statements,” we believe the following accounting policies are critical to the process of making significant judgments and estimates in preparation of our condensed financial statements.

Cash, Cash Equivalents, including US Treasury Market Fund

As of March 31, 2025 and June 30, 2024 our cash and cash equivalents totaled $2,858,963 and $2,071,016 respectively with the majority invested in a short-term US Treasury Fund returning approximately 5%. The Fund is invested in US Treasuries with a 7-day liquidity. The decision to allocate funds to the short-term US Treasury Fund is based on our investment strategy, which prioritizes liquidity and stability while receiving current rate returns. The returns from the fund for the nine months ended March 31, 2025 and 2024 were 4.9% and 5.0%, respectively, and in line with our expectations and the broader market trends for similar investment vehicles. We continuously monitor our investment portfolio, considering market conditions and our liquidity needs, ensuring alignment with our broader financial strategy and risk tolerance.

Internally-Developed Capitalized Software

We capitalize certain costs related to the development of software for our customers, primarily consisting of direct labor and third-party vendor costs associated with creating the software. Software development projects generally include three stages: the preliminary project stage (all costs are expensed as incurred), the application development stage (certain costs are capitalized and certain costs are expensed as incurred) and the post-implementation/operation stage (all costs are expensed as incurred). Costs capitalized in the application development stage include costs related to the design and implementation of the selected software components, software build and configuration infrastructure, and software interfaces. Capitalization of costs requires judgment in determining when a project has reached the application development stage, the proportion of time spent in the application development stage, and the period over which we expect to benefit from the use of that software. Once the software is placed in service, these costs are amortized on the straight-line method over the estimated useful life of the software, which is generally three years.

The Company capitalized software of $292,200 and $227,600 and recognized amortization expense of $312,709 and $395,165 for the nine months ended March 31, 2025 and 2024, respectively.

-17-

Revenue Recognition

We generate substantially all our revenue from contractual arrangements with our clients to provide a comprehensive platform of tightly integrated technology and technology-enabled services related to product offerings. Revenue related to our licensing arrangements is generally recognized ratably over the contract term commencing upon platform delivery. Revenue related to licensing arrangements recognized in a given time period will consist of contracts that went live in the current period or that went live in previous periods and are currently ongoing.

We have recorded accounts receivable of $4,440 and $30,060 as of March 31, 2025 and June 30, 2024, respectively. We have set up deferred revenue liabilities at the end of each period to reflect performance obligations to be performed in future periods for our services delivered over time. Future obligations related to deferred revenue totaled $3,835 and $0 as of March 31, 2025 and June 30, 2024 respectively.

Results of Operations

Revenue

We generated revenues of approximately $31,000 for the three months ended March 31, 2025 as compared to $34,000 for the three months ended March 31, 2024. We generated revenues of approximately $55,000 for the nine months ended March 31, 2025 as compared to $139,000 for the nine months ended March 31, 2024.

We have strongly pivoted to growing our customer base while reducing risk and losses, resulting in a larger client base, a short-term reduction in overall revenue and a dramatic reduction in cash burn. Larger, cash-upfront deals were struggling to produce sustainable revenue, as administrative barriers within nonprofits, high price points set by customers, and inability or unwillingness of customers to partner with schools, businesses and other entities to purchase products hampered growth.

We continue to believe that AI-powered B2B and B2C solutions, priced affordably, will supplant other similar products in the mid to long term. We have focused all new development work on delivering AI tools to markets hungry for increased capability that immediately impacts both their performance and their bottom line. The NurseMagic^TM app is the first of these and has already gained traction with larger entities.

Stock-Based Compensation

We issue four types of stock-based awards under our stock plans: stock options, restricted stock units, deferred stock units, and stock warrants. All stock-based awards granted to employees, directors and independent contractors are measured at fair value at each grant date. We rely on the Black-Scholes option pricing model for estimating the fair value of stock-based awards granted, and expected volatility is based on the historical volatility of the Company’s stock prices. Stock options generally vest over two years from the grant date and generally have ten-year contractual terms. Restricted stock units generally have a term of 12 months from the closing date of the agreement. Stock warrants issued have a term of five years. Information about the assumptions used in the calculation of stock-based compensation expense is set forth in Note 3 in the Notes to Condensed Financial Statements.

General and Administrative

General and administrative expenses consist primarily of personnel and personnel-related expenses, including executive management, legal, finance, human resources and other departments that do not provide direct operational services. General and administrative expenses also include professional fees and other corporate expenses.

General and administrative expenses for the three months ended March 31, 2025 were approximately $428,000 as compared to approximately $1,135,000 for the three months ended March 31, 2024. The decrease is largely attributable to a reduction in stock-based compensation. General and administrative expenses for the nine months ended March 31, 2025 were approximately $1,866,000 as compared to $2,017,000 for the nine months ended March 31, 2024. This decrease is primarily attributable to a reduction in stock-based compensation.

-18-

Technology and Content Development

Technology and content development expenses consist primarily of personnel and personnel-related expenses and contracted services associated with the ongoing improvement and maintenance of our platform as well as hosting and licensing costs. Technology and content expenses also include the amortization of capitalized software costs.

Technology and content development expenses for the three months ended March 31, 2025 were approximately $172,000 as compared to approximately $224,000 for the three months ended March 31, 2024. Technology and content development expenses for the nine months ended March 31, 2025 were approximately $524,000 as compared to $889,000 for the nine months ended March 31, 2024. The decrease is principally related to reductions in headcount and associated administrative costs, reflecting the completion of certain programs that are now offered to our customers and require less staffing to maintain than to build.

Sales and Marketing

Sales and marketing expense consist primarily of activities to attract customers to our offerings. This includes personnel and personnel-related expenses, various search engine and social media costs as well as the cost of advertising.

Sales and marketing expenses for the three months ended March 31, 2025 were approximately $118,000 as compared to approximately $139,000 for the three months ended March 31, 2024. Sales and marketing expenses for the nine months ended March 31, 2025 were approximately $411,000 as compared to $603,000 for the nine months ended March 31, 2024. The decrease is principally related to refinement of sales and marketing processes to those that focus messaging directly to our key markets and offer improved lead generation. We have seen increases in marketing qualified leads (MQLs) in both periods, while reducing the overall sales and marketing spends.

Interest Income

For the three months ended March 31, 2025, interest income approximated $24,000 as compared to interest income of $38,000 for the three months ended March 31, 2024. For the nine months ended March 31, 2025, interest income approximated $53,000, as compared to interest income of $148,000 for the nine months ended March 31, 2024.

Net Loss

Our net loss for the three months ended March 31, 2025 was approximately $663,000 as compared to a net loss for the three months ended March 31, 2024 of approximately $1.4 million. The loss for the nine months ended March 31, 2025 was approximately $2.7 million, as compared to $3.2 million for the nine months ended March 31, 2024. The loss was about 16% lower during the nine months ended March 31, 2025 compared to the nine months ended March 31, 2024 as a result of decreased stock compensation and decreases in technology and content development and sales and marketing as discussed above.

-19-

Capital Expenditures

During the nine months ended March 31, 2025 and 2024, we had capital asset additions of $292,200 and $228,000, respectively, in capitalized technology and content development. We will continue to capitalize significant software development costs, comprised primarily of internal payroll, payroll related and contractor costs, as we build out and complete our technology platform.

Nasdaq Deficiency Letter

On November 26, 2024, the Company received a deficiency letter (the “Nasdaq Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Stockholders’ Equity Requirement”), nor was it in compliance with either of the alternative listing standards, either a market value of listed securities of at least $35 million or net income of $500,000 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years.

Pursuant to the Nasdaq Letter, the Company had 45 calendar days from the date of the Nasdaq Letter to submit a plan to regain compliance. On January 10, 2025, the Company submitted a plan to regain compliance. In addition, on January 10, 2025, the Company filed a Current Report on Form 8-K reporting that as a result of the Company’s January 2025 public offering, that it believed that it had regained compliance with the Stockholders’ Equity Requirement. On January 23, 2025, the Company received written notice from Nasdaq that based on the Company’s Form 8-K dated January 10, 2025, Nasdaq has determined that the Company complies with the Stockholders’ Equity Requirement and that if the Company fails to evidence compliance upon filing its next periodic report it may be subject to delisting, at which time Nasdaq will provide written notification to the Company, which the Company may then appeal to a Hearings Panel.

The Company intends to take all reasonable measures available to maintain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. However, there can be no assurance that the Company will be successful in maintaining compliance with the Stockholders’ Equity Requirement and all applicable requirements for continued listing.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

-20-

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

The Company is not required to provide the information required by this Item as it is a “smaller reporting company.”

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision, and with the participation of, our management, including our Chief Executive Officer (principal executive officer) and our Chief Financial Officer (principal financial and accounting officer), of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (“Exchange Act”). Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective due to certain identified material weaknesses.

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

Specifically, our management concluded that we did not have existing controls and procedures to review and approve journal entries, and that we did not design control(s) procedures (i) to ensure that stock compensation expense is correctly calculated and recorded for employees, (ii) over the classification of stock-based compensation, and (iii) to ensure that deferred revenue is only recorded when payment is received in advance of fulfilling performance obligations.

Remediation Efforts to Address the Material Weaknesses

With the oversight of senior management and our audit committee, we are taking the steps below and plan to take additional measures to remediate the underlying causes of the material weaknesses:

●

The Company will take steps to remediate the material weaknesses through the documentation of processes and controls for transactions that occur in the course of business, and in the financial statement close, reporting and disclosure processes.

●

The Company will formalize our process and documentation for monitoring internal control over financial reporting. The documentation will serve as the evidence to ascertain whether the control activities are present and functioning, and provide a foundation for the Company to communicate internal control deficiencies in a timely manner to those parties responsible for taking corrective action.

In addition, under the direction of the audit committee of the Board of Directors, management will continue to review and make necessary changes to the overall design of the Company’s internal control environment, as well as to refine policies and procedures to improve the overall effectiveness of internal control over financial reporting of the Company.

We cannot be assured that the measures we have taken to date, or plan to implement, will be sufficient to remediate the material weaknesses we have identified or avoid potential future material weaknesses.

Changes in Internal Controls Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the period ended March 31, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

-21-

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

None.

Item 1A. Risk Factors.

Our business, financial condition, results of operations, and cash flows may be impacted by a number of factors, many of which are beyond our control, including those set forth in our Annual Report on Form 10-K/A, the occurrence of any one of which could have a material adverse effect on our actual results. There have been no material changes in our risk factors from those previously disclosed in our Annual Report on Form 10-K/A.

If we are unable to comply with the continued listing requirements of the Nasdaq Capital Market, then our common stock would be delisted from the Nasdaq Capital Market, which would limit investors’ ability to effect transactions in our common stock and subject us to additional trading restrictions.

Neither the Nasdaq Letter nor our noncompliance have an immediate effect on the listing or trading of our common shares, which will continue to trade on the Nasdaq Capital Market under the symbol “AMST.”

If the Nasdaq Capital Market delists our common stock from trading on its exchange and we are not able to list our securities on another national securities exchange, we expect the common stock would qualify to be quoted on an over-the-counter market. If this were to occur, we could face significant material adverse consequences, including:

●

a limited availability of market quotations for our securities;

●

reduced liquidity for our securities;

-22-

●

substantially impair our ability to raise additional funds;

●

the loss of institutional investor interest and a decreased ability to issue additional securities or obtain additional financing in the future;

●

a determination that our common stock is a “penny stock,” which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;

●

a limited amount of news and analyst coverage; and

●

potential breaches of representations or covenants of our agreements pursuant to which we made representations or covenants relating to our compliance with applicable listing requirements, which, regardless of merit, could result in costly litigation, significant liabilities and diversion of our management’s time and attention and could have a material adverse effect on our financial condition, business and results of operations.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

During the quarter ended March 31, 2025, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.

-23-

Item 6. Exhibits

Exhibit

Incorporated by Reference

Filed

Number

Exhibit Description

Form

File No.

Exhibit

Filing Date

Herewith

3.1

Certificate of Incorporation of the Registrant

10-Q

001-39553

3.1

November 16, 2020

3.2

Certificate of Designations of Series A Preferred Stock, dated January 13, 2023

8-K

001-39553

3.1

January 13, 2023

3.3

Certificate of Amendment to Certificate of Incorporation of Amesite Inc. dated February 16, 2023

8-K

001-39553

3.1

February 21, 2023

3.4

Bylaws of the Registrant, as amended

4.1

Form of Underwriters’ Warrant

8-K

001-39553

4.1

January 10, 2025

10.1

Underwriting Agreement, dated January 7, 2025, by and between the Company and Laidlaw & Company (UK) Ltd., as representative of the several underwriters listed in Schedule I thereto.

8-K

001-39553

1.1

January 10, 2025

31.1

Certification of Chief Executive Officer filed pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a) of the Securities and Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification of Chief Financial Officer filed pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a) of the Securities and Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*

Certification by Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*

Certification by Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

Inline XBRL Instance Document

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File - the cover page from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 is formatted in Inline XBRL

This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.

-24-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	AMESITE INC.

Date: May 15, 2025	By:	/s/ Ann Marie Sastry
		Ann Marie Sastry, Ph.D.
		Chief Executive Officer
		(Principal Executive Officer)

Date: May 15, 2025	By:	/s/ Sarah Berman
		Sarah Berman
		Principal Financial and Accounting Officer
		(Principal Financial Officer)
		(Principal Accounting Officer)

-25-

http://fasb.org/us-gaap/2025#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember 0001807166 false Q3 --06-30 0001807166 2024-07-01 2025-03-31 0001807166 2025-05-15 0001807166 2025-03-31 0001807166 2024-06-30 0001807166 2025-01-01 2025-03-31 0001807166 2024-01-01 2024-03-31 0001807166 2023-07-01 2024-03-31 0001807166 us-gaap:CommonStockMember 2024-06-30 0001807166 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001807166 us-gaap:RetainedEarningsMember 2024-06-30 0001807166 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001807166 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001807166 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001807166 2024-07-01 2024-09-30 0001807166 us-gaap:CommonStockMember 2024-09-30 0001807166 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001807166 us-gaap:RetainedEarningsMember 2024-09-30 0001807166 2024-09-30 0001807166 us-gaap:CommonStockMember 2024-10-01 2024-12-31 0001807166 us-gaap:AdditionalPaidInCapitalMember 2024-10-01 2024-12-31 0001807166 us-gaap:RetainedEarningsMember 2024-10-01 2024-12-31 0001807166 2024-10-01 2024-12-31 0001807166 us-gaap:CommonStockMember 2024-12-31 0001807166 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001807166 us-gaap:RetainedEarningsMember 2024-12-31 0001807166 2024-12-31 0001807166 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001807166 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001807166 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001807166 us-gaap:CommonStockMember 2025-03-31 0001807166 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001807166 us-gaap:RetainedEarningsMember 2025-03-31 0001807166 us-gaap:CommonStockMember 2023-06-30 0001807166 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001807166 us-gaap:RetainedEarningsMember 2023-06-30 0001807166 2023-06-30 0001807166 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001807166 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001807166 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001807166 2023-07-01 2023-09-30 0001807166 us-gaap:CommonStockMember 2023-09-30 0001807166 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001807166 us-gaap:RetainedEarningsMember 2023-09-30 0001807166 2023-09-30 0001807166 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001807166 us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2023-12-31 0001807166 us-gaap:RetainedEarningsMember 2023-10-01 2023-12-31 0001807166 2023-10-01 2023-12-31 0001807166 us-gaap:CommonStockMember 2023-12-31 0001807166 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001807166 us-gaap:RetainedEarningsMember 2023-12-31 0001807166 2023-12-31 0001807166 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001807166 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001807166 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001807166 us-gaap:CommonStockMember 2024-03-31 0001807166 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001807166 us-gaap:RetainedEarningsMember 2024-03-31 0001807166 2024-03-31 0001807166 amst:TechnologyAndContentDevelopmentMember 2024-07-01 2025-03-31 0001807166 amst:TechnologyAndContentDevelopmentMember 2023-07-01 2024-03-31 0001807166 us-gaap:OtherCustomerMember 2024-07-01 2025-03-31 0001807166 us-gaap:OtherCustomerMember 2023-07-01 2024-03-31 0001807166 amst:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0001807166 amst:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2025-03-31 0001807166 us-gaap:OtherCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001807166 us-gaap:OtherCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2024-03-31 0001807166 2023-07-01 2024-06-30 0001807166 us-gaap:LeaseholdImprovementsMember 2025-03-31 0001807166 us-gaap:FurnitureAndFixturesMember 2025-03-31 0001807166 us-gaap:ComputerEquipmentMember 2025-03-31 0001807166 2021-09-29 2021-09-29 0001807166 amst:CompensationCommitteeMember 2021-09-29 2021-09-29 0001807166 amst:AuditCommitteeMember 2021-09-29 2021-09-29 0001807166 amst:DeferredStockUnitsMember 2024-07-01 2025-03-31 0001807166 amst:CashCompensationMember 2024-07-01 2025-03-31 0001807166 amst:DeferredStockUnitsMember 2025-01-01 2025-03-31 0001807166 srt:BoardOfDirectorsChairmanMember us-gaap:CommonStockMember 2024-07-01 2025-03-31 0001807166 srt:BoardOfDirectorsChairmanMember 2021-09-29 2021-09-29 0001807166 amst:TwothousandeighteenEquityIncentivePlanMember 2024-05-03 0001807166 amst:TwothousandeighteenEquityIncentivePlanMember 2024-05-03 2024-05-03 0001807166 2024-07-11 0001807166 srt:BoardOfDirectorsChairmanMember 2025-03-07 0001807166 2025-03-07 2025-03-07 0001807166 srt:BoardOfDirectorsChairmanMember amst:DeferredStockUnitsMember 2023-07-01 2024-06-30 0001807166 amst:TwentyTwentyTwoRestrictedStockUnitGrantMember 2024-07-01 2025-03-31 0001807166 amst:TwentyTwentyFourRestrictedStockUnitGrantsMember 2023-07-01 2024-06-30 0001807166 srt:BoardOfDirectorsChairmanMember 2024-07-01 2025-03-31 0001807166 srt:ChiefExecutiveOfficerMember 2024-07-01 2025-03-31 0001807166 2024-06-30 2024-06-30 0001807166 2024-12-31 2024-12-31 0001807166 amst:DeferredStockUnitsMember 2024-06-30 0001807166 amst:DeferredStockUnitsMember 2025-03-31 0001807166 amst:DeferredStockUnitsMember 2024-12-31 0001807166 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001807166 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2025-03-31 0001807166 us-gaap:RestrictedStockUnitsRSUMember 2025-03-31 0001807166 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001807166 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-03-31 0001807166 amst:LaidlawCompanyUKLtdMember 2025-01-07 2025-01-07 0001807166 amst:LaidlawCompanyUKLtdMember 2025-01-07 0001807166 2025-01-07 0001807166 2025-01-07 2025-01-07 0001807166 us-gaap:MeasurementInputPriceVolatilityMember 2025-01-07 0001807166 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-01-07 0001807166 us-gaap:WarrantMember 2024-06-30 0001807166 us-gaap:WarrantMember 2024-06-30 2024-06-30 0001807166 us-gaap:WarrantMember 2024-07-01 2025-03-31 0001807166 us-gaap:WarrantMember 2025-03-31 0001807166 amst:TaxYear2037Member 2025-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

Amesite Inc. 10-Q